Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Amazon Explores AI Content Marketplace With Media Publishers 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
SAN DIEGO, Jan. 09, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a novel bioinformatics tool that makes it easy for researchers to understand drug combination effects. CrownSyn™ is now available as an add-on feature to all two-drug combinatorial studies conducted by Crown Bioscience.
Combination therapies can improve efficacy, overcome drug resistance and decrease toxicity. They are an increasingly important treatment modality for several complex conditions including cancer, inflammatory, autoimmune, neurodegenerative, cardiovascular and metabolic diseases. To help our clients evaluate the efficacy of two-drug combinations, Crown Bioscience’s expert team of bioinformaticians developed CrownSyn™. CrownSyn™ is a tool that helps clients visualize and characterize combination effects as synergistic, antagonistic, and additive as well as determine optimal doses for further safety and efficacy studies. CrownSyn™ makes well-validated computational methods from published papers readily available to biologists.
CrownSyn™ is compatible with most experimental designs and provides dose-response curve graphs, combination index graphs, inhibition heat maps for concentration combinations, 2-D contour maps and 3D response surface plots. This assortment of graphical outputs makes it easy for clients to select efficacious combinations to advance their preclinical development programs.
“Combination therapies are a cornerstone for the treatment of complex diseases like resistant and metastatic cancers, cardiovascular, metabolic and inflammatory diseases,” said Laurie Heilmann, Crown Bioscience’s Chief Business Officer. “CrownSyn™ is CrownBio’s latest contribution to help our clients progress innovative drug development programs aimed at treating these complicated conditions with combination therapies.”
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
